Oculis Holding AG (OCS)
| Market Cap | 509.91M -54.8% |
| Revenue (ttm) | 1.45M +53.5% |
| Net Income | -98.01M |
| EPS | -1.72 |
| Shares Out | 61.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 309,697 |
| Open | 8.19 |
| Previous Close | 8.24 |
| Day's Range | 8.19 - 8.84 |
| 52-Week Range | 7.11 - 34.48 |
| Beta | 0.27 |
| Analysts | Strong Buy |
| Price Target | 37.01 (+348.06%) |
| Earnings Date | Nov 3, 2026 |
About OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da... [Read more]
Financial Performance
In 2025, Oculis Holding AG's revenue was 1.20 million, an increase of 74.78% compared to the previous year's 686,000. Losses were -98.96 million, 15.4% more than in 2024.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for OCS stock is "Strong Buy." The 12-month stock price target is $37.01, which is an increase of 348.06% from the latest price.
News
Oculis to Feature Privosegtor's Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
Positive Phase 2 ACUITY trial findings support Privosegtor's potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond
Oculis reports Phase 2 data supporting Privosegtor in optic neuritis
Oculis (OCS) announced new translational biomarker data from the Phase 2 ACUITY trial of Privosegtor in patients with optic neuritis. Increases in plasma neurofilament light chain and plasma glial fib...
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa ...
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials
Oculis Holding AG Slides: Study presentation
Oculis Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on October 12, 2026.
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end
Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS
Oculis and the National Multiple Sclerosis Society's campaign share a common goal to accelerate breakthroughs in MS research and improve patients' quality of life
Oculis Announces Resignation of Lionel Carnot from Board of Directors
ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address signi...
Oculis price target raised to $39 from $26 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Oculis (OCS) to $39 from $26 and keeps a Buy rating on the shares. The company’s PREDICT-1 trial of…
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company's Board of Directors.
Oculis Holding AG Transcript: 2026 Global Healthcare Conference
Two late-stage programs are advancing: Licaminlimab for TNFR1 dry eye, using a precision medicine approach with a phase III readout expected late 2026/early 2027, and Privosegtor for acute optic neuritis, now in global phase III after strong phase II results. Expansion into MS relapses and NAION is planned, with robust financing supporting all clinical activities.
Oculis Holding AG Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Precision medicine is central to ongoing trials, with TNFR1 biomarker enrichment guiding patient selection and regulatory strategy. Key programs are fully funded through 2029, and recent asset acquisitions have improved cost structure and flexibility.
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today ...
Oculis price target lowered to $20 from $23 at JPMorgan
JPMorgan lowered the firm’s price target on Oculis (OCS) to $20 from $23 and keeps an Overweight rating on the shares.
Oculis price target lowered to $32 from $35 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Oculis (OCS) to $32 from $35 and keeps a Buy rating on the shares. The firm adjusted targets for several…
Oculis to acquire development, commercial rights to Privosegtor from Accure
Oculis (OCS) and Accure Therapeutics announced that Oculis and Accure have entered into an asset purchase agreement whereby, upon closing, Oculis will acquire all of Accure’s worldwide development and...
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company
ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations t...
Oculis reports Q2 EPS (16c), consensus (38c)
Riad Sherif, Chief Executive Officer of Oculis (OCS), stated, “We continue to advance and expand the Privosegtor neuroprotection franchise, with PIONEER-1 on track in global site activations and posit...
Oculis Reports Q2 2026 Financial Results and Provides Company Update
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant ...
Oculis Holding AG Earnings release: Q2 2026
Oculis Holding AG released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Oculis gets FDA pre-IND feedback regarding Privosegtor clinical development plan
Oculis (OCS) announced FDA pre-IND feedback regarding Privosegtor’s clinical development plan in acute multiple sclerosis relapses. Privosegtor is a peptoid small-molecule candidate with potential neu...
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to a...